M&A Deal Summary |
|
---|---|
Date | 2021-08-16 |
Target | Genuity Science |
Sector | Life Science |
Buyer(s) | Hibercell |
Deal Type | Add-on Acquisition |
Deal Value | 100M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Hibercell is a clinical-stage biotechnology company focused on the advancement of novel therapeutic molecules that overcome the foundational molecular barriers that prevent patients from living longer, cancer-free lives. HiberCell’s approach utilizes the AI/ML to integrate both the genomic and phenotypic profiles of a patient’s cancer to generate deep insights that connect these data to clinical outcomes to identify the causal features that can be targeted with novel therapies that address the most common cause of cancer mortality: resistance, relapse, and metastasis. Hibercell was founded in 2019 and is based in New York City.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (Massachusetts) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 1 |